Similar Items: A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025
- Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges
- Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib
- Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer
- Benign Bronchial Tumours: A Rare Case of Endobronchial Fibroma With Hilar–Mediastinal Lymphadenopathy
- BAL Flow Cytometry Unmasks Nodal T Follicular Helper Cell Lymphoma–Associated Hemophagocytic Lymphohistiocytosis When Bone Marrow Is Nondiagnostic: A Case Report
- Potential Dupilumab-Induced Unmasking of Specific Immunoglobulin Deficiency: A First-of-Its-Kind Case